Arcus Current Deferred Revenue from 2010 to 2024
| RCUS Stock | USD 15.94 0.50 3.24% |
Current Deferred Revenue | First Reported 2017-12-31 | Previous Quarter 113 M | Current Value 105 M | Quarterly Volatility 46.1 M |
Check Arcus Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Arcus Biosciences' main balance sheet or income statement drivers, such as Net Interest Income of 41 M, Interest Income of 43 M or Depreciation And Amortization of 6.1 M, as well as many indicators such as Price To Sales Ratio of 11.48, Dividend Yield of 0.0 or PTB Ratio of 3.39. Arcus financial statements analysis is a perfect complement when working with Arcus Biosciences Valuation or Volatility modules.
Arcus | Current Deferred Revenue |
Latest Arcus Biosciences' Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of Arcus Biosciences over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. Arcus Biosciences' Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Arcus Biosciences' overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
Arcus Current Deferred Revenue Regression Statistics
| Arithmetic Mean | 31,865,470 | |
| Geometric Mean | 13,261,781 | |
| Coefficient Of Variation | 125.34 | |
| Mean Deviation | 35,387,294 | |
| Median | 5,000,000 | |
| Standard Deviation | 39,938,683 | |
| Sample Variance | 1595.1T | |
| Range | 97M | |
| R-Value | 0.79 | |
| Mean Square Error | 658T | |
| R-Squared | 0.62 | |
| Significance | 0.0005 | |
| Slope | 7,014,576 | |
| Total Sum of Squares | 22331.4T |
Arcus Current Deferred Revenue History
About Arcus Biosciences Financial Statements
Arcus Biosciences shareholders use historical fundamental indicators, such as Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Although Arcus Biosciences investors may analyze each financial statement separately, they are all interrelated. The changes in Arcus Biosciences' assets and liabilities, for example, are also reflected in the revenues and expenses on on Arcus Biosciences' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 91 M | 60.2 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Arcus Stock Analysis
When running Arcus Biosciences' price analysis, check to measure Arcus Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcus Biosciences is operating at the current time. Most of Arcus Biosciences' value examination focuses on studying past and present price action to predict the probability of Arcus Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcus Biosciences' price. Additionally, you may evaluate how the addition of Arcus Biosciences to your portfolios can decrease your overall portfolio volatility.